Transparency Market Research Report Added "Single Agent Chemotherapy Market" to its database.
Albany, NY -- (SBWIRE) -- 04/05/2016 -- A new market research report by Transparency Market Research, titled "Single Agent Chemotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020," presents a detailed evaluation of the market and is extremely helpful in identifying the major unmet requirements within the market for single agent chemotherapy. The changes expected to be seen in the single agent chemotherapy market in forthcoming years due to numerous technological advancements have also been studied in detail under this study. In addition, the report also takes into account the current competition within the market in addition to providing knowledgeable insights into the prime market drivers, trends, restraints, opportunities, and challenges. All in all, the report scrutinizes the market for single agent chemotherapy on the basis of key segments, players, regions, and countries in the forecast horizon from 2014 to 2020.
As stated in the report, the devastating impacts in numerous cases of combination therapy and the increasing cost of treatment related to multiple agents are amongst the chief factors fuelling the market for single agent chemotherapy. In addition, the increasing count of cancer patients worldwide will further augment the development of the market owing to the fact that chemotherapy is amongst the most effective cancer treatments. On the other hand, over the period of treatment, the rising resistance against chemotherapy agents is a prime factor inhibiting the growth of the market. In addition, the delay in tumor response rates in comparison with combination therapy is also a chief factor impeding the growth of the market.
As mentioned in the report, the most popular single agent chemotherapy drugs are Fludarabine, Chlorambucil, Bendamustine, Teniposide, Mitomycin, Vinblastine, Dacarbazine, Procarbazine, Carboplatin, Doxorubicin, Ado-Trastuzumab, Ramucirumab, and Imatinib. On the basis of type of cancer, the market is segmented into breast cancer, gastrointestinal cancer, lung cancer, genitourinary cancer, endocrine cancer, head and neck cancer, gynecologic cancers, brain cancer, blood cancer, and others. Amongst these, the segment of breast cancer led the market in 2013. In terms of class, the report segments the market for single agent chemotherapy into antimetabolites, anti-tumor antibiotics, alkylating agents, mitotic inhibitors, and miscellaneous single chemotherapy drugs.
Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3953
In terms of geography, the market is segmented into Europe, Asia Pacific, North America, and Rest of the World (RoW). Among these, North America held the largest share in the market in 2013 and was trailed by Europe. The reason for the superiority of North America is the increasing occurrence of cancer and the rising R&D activities for drug development in this region. On the other hand, Asia Pacific is predicted to be amongst the most swiftly developing markets in the forecast horizon owing to the improvement in the economic condition of nations such as Malaysia, India, and China.
Sanofi-Aventis, Pfizer Inc., Schering-Plough, Bristol-Myers Squibb, and Roche are amongst the prominent players in the market.
Mr. Sudip S
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453